Biotech giant Regeneron Pharmaceuticals (REGN) said Monday that sales of its linchpin Eylea drug in the final quarter of 2022 were hurt by a shift to an off-label competitor. REGN stock plunged on the...
Biotech giant Regeneron Pharmaceuticals (REGN) said Monday that sales of its linchpin Eylea drug in the final quarter of 2022 were hurt by a shift to an off-label competitor. REGN stock plunged on the...